chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 43.0
Sex: F
Vaccine: COVID19, FLU4
Symptoms: Arthralgia, Muscular weakness, Pain, Pain in extremity
Clinical narrative: 12/20/23 patient reported to pharmacy with complaints of sore shoulder, pain in arm, shoulder and arm weakness and soreness, pain radiating to cervical vertabrae
Age: 66.0
Sex: F
Vaccine: RSV
Symptoms: Erythema, Lethargy, Mobility decreased, Peripheral swelling
Clinical narrative: Patient reports first day after vaccination being immobile and lethargic.  Second day after vaccination red and swollen arm.
Age: 69.0
Sex: F
Vaccine: FLU4
Symptoms: Wrong product administered
Clinical narrative: Patient should have received High Dose Flu vaccine and received a regular dose of the flu vaccine.
Age: 70.0
Sex: M
Vaccine: VARZOS
Symptoms: Anxiety, Asthenia, Atrial fibrillation, Chills, Condition aggravated
Clinical narrative: Patient was in usual state of health, Received second dose of Shingrix vaccine.  Subsequently we received a telephone call 2 days later from wife stating that patient was experiencing nausea, chills, generalized weakness, he was recommended supportive treatment at the time with Zofran to be sent over to help with nausea and recommended fluids and reevaluation in 24 hours. if not better.  Wife called back the next day stating that patient was feeling anxious had chills,  feeling hot with no fever and reports Zofran did not help him with his symptoms, he was advised to present to the ER on December 14 for evaluation, was noted to have chills and tremors, diagnosed with A-fib with RVR IN ER and treated with potassium, amiodarone, magnesium, sodium and ondansetron.  It appears that due to patient's presenting symptoms of nausea and feeling unwell,  he had also lapsed in  his usual  medications as he was feeling unwell preceding his ER presentation.  He was found to have A-fib with RVR, started on Xarelto, continued on propranolol and discharged home with outpatient cardiology and PCP follow-up. Patient reported to me that some hospital providers thought His  presenting symptoms could be vaccine related, others thought it was related to him not, being able to take his medications as a result of nausea and feeling sick, that could have triggered A-fib episode.
Age: 70.0
Sex: M
Vaccine: VARZOS
Symptoms: Echocardiogram, Electrocardiogram, Feeling hot, Malaise, Nausea
Clinical narrative: Patient was in usual state of health, Received second dose of Shingrix vaccine.  Subsequently we received a telephone call 2 days later from wife stating that patient was experiencing nausea, chills, generalized weakness, he was recommended supportive treatment at the time with Zofran to be sent over to help with nausea and recommended fluids and reevaluation in 24 hours. if not better.  Wife called back the next day stating that patient was feeling anxious had chills,  feeling hot with no fever and reports Zofran did not help him with his symptoms, he was advised to present to the ER on December 14 for evaluation, was noted to have chills and tremors, diagnosed with A-fib with RVR IN ER and treated with potassium, amiodarone, magnesium, sodium and ondansetron.  It appears that due to patient's presenting symptoms of nausea and feeling unwell,  he had also lapsed in  his usual  medications as he was feeling unwell preceding his ER presentation.  He was found to have A-fib with RVR, started on Xarelto, continued on propranolol and discharged home with outpatient cardiology and PCP follow-up. Patient reported to me that some hospital providers thought His  presenting symptoms could be vaccine related, others thought it was related to him not, being able to take his medications as a result of nausea and feeling sick, that could have triggered A-fib episode.
Age: 70.0
Sex: M
Vaccine: VARZOS
Symptoms: Therapy interrupted, Tremor
Clinical narrative: Patient was in usual state of health, Received second dose of Shingrix vaccine.  Subsequently we received a telephone call 2 days later from wife stating that patient was experiencing nausea, chills, generalized weakness, he was recommended supportive treatment at the time with Zofran to be sent over to help with nausea and recommended fluids and reevaluation in 24 hours. if not better.  Wife called back the next day stating that patient was feeling anxious had chills,  feeling hot with no fever and reports Zofran did not help him with his symptoms, he was advised to present to the ER on December 14 for evaluation, was noted to have chills and tremors, diagnosed with A-fib with RVR IN ER and treated with potassium, amiodarone, magnesium, sodium and ondansetron.  It appears that due to patient's presenting symptoms of nausea and feeling unwell,  he had also lapsed in  his usual  medications as he was feeling unwell preceding his ER presentation.  He was found to have A-fib with RVR, started on Xarelto, continued on propranolol and discharged home with outpatient cardiology and PCP follow-up. Patient reported to me that some hospital providers thought His  presenting symptoms could be vaccine related, others thought it was related to him not, being able to take his medications as a result of nausea and feeling sick, that could have triggered A-fib episode.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Headache, Mobility decreased, Oral pain, Pyrexia
Clinical narrative: Vaccine administered approximately 11:20 am, and patient experienced headache and fever within several hours which lasted for 2 days. The next day after administration she experienced severe pain in the roof of her mouth requiring over-the-counter pain medications. She also experienced severe weakness to the point where she could not get out of bed. Since then the only adverse effect the patient is experiencing  some weakness.
Age: 51.0
Sex: M
Vaccine: VARZOS
Symptoms: Burning sensation, Herpes zoster, Paraesthesia, Rash
Clinical narrative: Blistering rashes appeared on my left upper leg (groin area) about 2-3 days after vaccine. I went to the doctor on Thurs 12/14. Physician assistant believed the rashes were shingles and immediately started me on antiviral medication. I asked if the rashes could be a reaction to the shingrix vaccine, and she had not seen that before but thought I should contact CDC to explore further. Rashes gave me a burning sensation (i.e., not itchy). I also noticed "burning/tingling" without any rashes on the same left leg, on my quad not too far from the rashes. As of today, the rashes are still present but much better and seem to be going away.
Age: 41.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: We accidentally pulled expired vaccine (use before 12-13-2023) and gave to pt.   I contacted Pfizer and they said there is no impact on vaccines stability for 2 days past expiration, but they do not have stability date on 3 days past.  Called CDC and they said if vaccine was expired, it is invalid and pt needs to receive another dose in 8 weeks.  I followed up with patient and patient said he has not experienced any side effected.  patient seemed not too upset and understood the situation and he said he will be back in 8 weeks to get correct vaccine.
Age: 55.0
Sex: M
Vaccine: HEP
Symptoms: Hypersensitivity, Urticaria
Clinical narrative: About a week later, during/immediately after an episode of extreme overexertion, observed large raised purple bumps (hives, a severe allergic reaction) on inside of right arm at elbow.  These subsided quickly over the following days (during which I was able to rest).
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: We accidentally pulled expired vaccine 12-2024  (use before 12-13-2023) and gave to patient.   I contacted Pfizer and they said there is no impact on vaccines stability for 2 days past expiration, but they do not have stability date on 3 days past.  Called agency and they said if vaccine was expired, it is invalid and patient needs to receive another dose in 8 weeks. I followed up with patient and she said she will receive correct dose in 8 weeks
Age: 0.33
Sex: M
Vaccine: DTAPIPVHIB, DTPPVHBHPB, RV5
Symptoms: Extra dose administered
Clinical narrative: None stated.
Age: 10.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Nurse gave 0.25 ml of the Dark blue cap/ blue label for 12 years+ instead of the dark blue cap/ green label for 6 mo-11 years.
Age: 71.0
Sex: F
Vaccine: RSV
Symptoms: Injection site erythema, Injection site pruritus, Injection site warmth
Clinical narrative: pt got redness, itchy at site of injection  starting same day, has stayed the same, not gone away, 3"x3" area,. warm to touch. asked what pharmacist what she should do. he stated that she should see her doctor since could possibly be infected. pt agreed to do that
Age: 74.0
Sex: F
Vaccine: HEPA
Symptoms: No adverse event, Underdose
Clinical narrative: This patient was given a Hep A peds dose instead of a adult Hep A. No adverse reaction.
Age: 40.0
Sex: F
Vaccine: RSV
Symptoms: Delivery, Exposure during pregnancy, Haemorrhage in pregnancy, Premature delivery, Premature rupture of membranes
Clinical narrative: I was 36+5 weeks pregnant, due date 12/22/23. Had no bleeding or any sign of being close to labor prior to the vaccine. I did have gestational diabetes controlled with insulin. I had the vaccine Wednesday afternoon and the next day I had bloody show at 1pm, water broke 4am Friday morning, and gave birth through vaginal delivery 3:15pm Friday afternoon. Baby was 5 lb 13 oz at birth with no other issues. To me, the timing is suspicious for the vaccine possibly being the cause of early delivery, especially since I had no signs of being close to labor before the vaccine and my previous pregnancy I was induced at 38 weeks due to insulin controlled gestational diabetes.
Age: 2.0
Sex: F
Vaccine: HEP
Symptoms: Wrong product administered
Clinical narrative: Hep A was ordered by the provider but Hep B was given to the patient on 12/15/23.  Mom was notified on 12/20/23.
Age: 75.0
Sex: F
Vaccine: RSV
Symptoms: Injection site pruritus, Injection site swelling
Clinical narrative: Patient complained of injection site swelling and itching. "Not bad, but wanted to let you know".
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Breakthrough COVID-19
Clinical narrative: Covid-19 Breakthrough Infection
Age: 80.0
Sex: M
Vaccine: HEPA
Symptoms: No adverse event, Underdose
Clinical narrative: This patient was given a peds dose of Hep A instead of the adult Hep A. No adverse reaction.
Age: 24.0
Sex: F
Vaccine: RAB, RAB, RAB
Symptoms: Dysphagia, Dyspnoea, Throat tightness
Clinical narrative: she had a reaction after her first vaccine on 1 Dec 23. She became SOB and felt like throat was closing. Used her epi pen and spouse called the Advice line. Told to call EMS. Had second dose today at 1200 and is now experiencing some SOB and it is hard to swallow. It isn't as bad as last time but not great.
Age: 7.0
Sex: M
Vaccine: COVID19
Symptoms: Anaemia, Blood culture negative, COVID-19, Chest X-ray normal, Condition aggravated
Clinical narrative: Name: Patient Date of Birth:  MRN:   Primary Care Physician at Discharge:  MD Hematologist/Oncologist:  MD Admission Date: 12/7/2023 Discharge Date: 12/10/2023  DETAILS OF HOSPITAL STAY:  PRESENTING PROBLEM: Febrile neutropenia  [D70.9, R50.81] Severe sepsis (HCC) [A41.9, R65.20]   HOSPITAL COURSE: Patient is a 7 y.o. male with PMHx T Cell ALL in remission, who is admitted with febrile neutopenia in the setting of COVIC-19.  Patient had been evaluated in the clinic for day 31 interim maintenance II therapy like COG ALL0434, but secondary to neutropenia did not meet parameter to proceed with therapy.   He had new cough and rhinorrhea, with known sick contacts, and thus a film array was obtained and notable for COVID-19.  Peds ID reviewed his case and he was found to be eligible for IV Remdesevir, (paxlovid ineligible due to age), however given his mild symptoms and necessity to admit for infusion, decision was made not to proceed.     He was discharged from clinic with plan for close follow-up.  Unfortunately, shortly after leaving, patient developed a fever of 102 and presented to the ER for further assessment.  No notable GI symptoms; at baseline eating, activity, and urination. No respiratory worsening. Fastbreak protocol was initiated with central/peripheral blood cultures drawn, fluid bolus and cefepime given.  CBC demonstrated persistent neutropenia with ANC 430.  CMP with mild transaminitis.  Procal 1.04 without evidence of bacterial pneumonia on CXR.  UA was negative for infection. He was admitted for further monitoring and treatment.  He was started on IV Remdesivir with loading dose (1mg/kg) given overnight and subsequent doses (0.5mg/kg) scheduled daily; maintained in severe respiratory precautions.    On 12/8, CBC showed worsening anemia and he received 1 unit pRBCs with excellent response.  He was continued on empiric Cefepime through 12/10. Blood cultures were NGTD at > 48 hours. He completed remdesivir 3 day course as clinically he remained well without significant complication of Covid infection. He had no further fevers during admission. CBC and CMP continued to be monitored daily and by the time of discharge, ANC was overall stable at 380.  Day 31 therapy was deferred to 12/11 with f/up scheduled in the PHO clinic.  It was discussed that he should remain with masking precautions for ongoing Covid infection for 21 days given immunocompromise and prolonged viral shedding with additional isolation as able thru 12/12 (apart from necessary medical appointments).   Father was advised to return for any further fevers > 101F and for worsening respiratory status as this could be indication of secondary bacterial pneumonia. All questions answered. Port was de-accessed prior to discharge.   His next LP will be deferred to 1/8/2024 with start of maintenance therapy.
Age: 7.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Exposure to communicable disease, Febrile neutropenia, Full blood count abnormal, Hypertransaminasaemia
Clinical narrative: Name: Patient Date of Birth:  MRN:   Primary Care Physician at Discharge:  MD Hematologist/Oncologist:  MD Admission Date: 12/7/2023 Discharge Date: 12/10/2023  DETAILS OF HOSPITAL STAY:  PRESENTING PROBLEM: Febrile neutropenia  [D70.9, R50.81] Severe sepsis (HCC) [A41.9, R65.20]   HOSPITAL COURSE: Patient is a 7 y.o. male with PMHx T Cell ALL in remission, who is admitted with febrile neutopenia in the setting of COVIC-19.  Patient had been evaluated in the clinic for day 31 interim maintenance II therapy like COG ALL0434, but secondary to neutropenia did not meet parameter to proceed with therapy.   He had new cough and rhinorrhea, with known sick contacts, and thus a film array was obtained and notable for COVID-19.  Peds ID reviewed his case and he was found to be eligible for IV Remdesevir, (paxlovid ineligible due to age), however given his mild symptoms and necessity to admit for infusion, decision was made not to proceed.     He was discharged from clinic with plan for close follow-up.  Unfortunately, shortly after leaving, patient developed a fever of 102 and presented to the ER for further assessment.  No notable GI symptoms; at baseline eating, activity, and urination. No respiratory worsening. Fastbreak protocol was initiated with central/peripheral blood cultures drawn, fluid bolus and cefepime given.  CBC demonstrated persistent neutropenia with ANC 430.  CMP with mild transaminitis.  Procal 1.04 without evidence of bacterial pneumonia on CXR.  UA was negative for infection. He was admitted for further monitoring and treatment.  He was started on IV Remdesivir with loading dose (1mg/kg) given overnight and subsequent doses (0.5mg/kg) scheduled daily; maintained in severe respiratory precautions.    On 12/8, CBC showed worsening anemia and he received 1 unit pRBCs with excellent response.  He was continued on empiric Cefepime through 12/10. Blood cultures were NGTD at > 48 hours. He completed remdesivir 3 day course as clinically he remained well without significant complication of Covid infection. He had no further fevers during admission. CBC and CMP continued to be monitored daily and by the time of discharge, ANC was overall stable at 380.  Day 31 therapy was deferred to 12/11 with f/up scheduled in the PHO clinic.  It was discussed that he should remain with masking precautions for ongoing Covid infection for 21 days given immunocompromise and prolonged viral shedding with additional isolation as able thru 12/12 (apart from necessary medical appointments).   Father was advised to return for any further fevers > 101F and for worsening respiratory status as this could be indication of secondary bacterial pneumonia. All questions answered. Port was de-accessed prior to discharge.   His next LP will be deferred to 1/8/2024 with start of maintenance therapy.
Age: 7.0
Sex: M
Vaccine: COVID19
Symptoms: Metabolic function test abnormal, Neutrophil count decreased, Procalcitonin, Pyrexia, Red blood cell transfusion
Clinical narrative: Name: Patient Date of Birth:  MRN:   Primary Care Physician at Discharge:  MD Hematologist/Oncologist:  MD Admission Date: 12/7/2023 Discharge Date: 12/10/2023  DETAILS OF HOSPITAL STAY:  PRESENTING PROBLEM: Febrile neutropenia  [D70.9, R50.81] Severe sepsis (HCC) [A41.9, R65.20]   HOSPITAL COURSE: Patient is a 7 y.o. male with PMHx T Cell ALL in remission, who is admitted with febrile neutopenia in the setting of COVIC-19.  Patient had been evaluated in the clinic for day 31 interim maintenance II therapy like COG ALL0434, but secondary to neutropenia did not meet parameter to proceed with therapy.   He had new cough and rhinorrhea, with known sick contacts, and thus a film array was obtained and notable for COVID-19.  Peds ID reviewed his case and he was found to be eligible for IV Remdesevir, (paxlovid ineligible due to age), however given his mild symptoms and necessity to admit for infusion, decision was made not to proceed.     He was discharged from clinic with plan for close follow-up.  Unfortunately, shortly after leaving, patient developed a fever of 102 and presented to the ER for further assessment.  No notable GI symptoms; at baseline eating, activity, and urination. No respiratory worsening. Fastbreak protocol was initiated with central/peripheral blood cultures drawn, fluid bolus and cefepime given.  CBC demonstrated persistent neutropenia with ANC 430.  CMP with mild transaminitis.  Procal 1.04 without evidence of bacterial pneumonia on CXR.  UA was negative for infection. He was admitted for further monitoring and treatment.  He was started on IV Remdesivir with loading dose (1mg/kg) given overnight and subsequent doses (0.5mg/kg) scheduled daily; maintained in severe respiratory precautions.    On 12/8, CBC showed worsening anemia and he received 1 unit pRBCs with excellent response.  He was continued on empiric Cefepime through 12/10. Blood cultures were NGTD at > 48 hours. He completed remdesivir 3 day course as clinically he remained well without significant complication of Covid infection. He had no further fevers during admission. CBC and CMP continued to be monitored daily and by the time of discharge, ANC was overall stable at 380.  Day 31 therapy was deferred to 12/11 with f/up scheduled in the PHO clinic.  It was discussed that he should remain with masking precautions for ongoing Covid infection for 21 days given immunocompromise and prolonged viral shedding with additional isolation as able thru 12/12 (apart from necessary medical appointments).   Father was advised to return for any further fevers > 101F and for worsening respiratory status as this could be indication of secondary bacterial pneumonia. All questions answered. Port was de-accessed prior to discharge.   His next LP will be deferred to 1/8/2024 with start of maintenance therapy.
Age: 7.0
Sex: M
Vaccine: COVID19
Symptoms: Rhinorrhoea, Sepsis, Urine analysis normal
Clinical narrative: Name: Patient Date of Birth:  MRN:   Primary Care Physician at Discharge:  MD Hematologist/Oncologist:  MD Admission Date: 12/7/2023 Discharge Date: 12/10/2023  DETAILS OF HOSPITAL STAY:  PRESENTING PROBLEM: Febrile neutropenia  [D70.9, R50.81] Severe sepsis (HCC) [A41.9, R65.20]   HOSPITAL COURSE: Patient is a 7 y.o. male with PMHx T Cell ALL in remission, who is admitted with febrile neutopenia in the setting of COVIC-19.  Patient had been evaluated in the clinic for day 31 interim maintenance II therapy like COG ALL0434, but secondary to neutropenia did not meet parameter to proceed with therapy.   He had new cough and rhinorrhea, with known sick contacts, and thus a film array was obtained and notable for COVID-19.  Peds ID reviewed his case and he was found to be eligible for IV Remdesevir, (paxlovid ineligible due to age), however given his mild symptoms and necessity to admit for infusion, decision was made not to proceed.     He was discharged from clinic with plan for close follow-up.  Unfortunately, shortly after leaving, patient developed a fever of 102 and presented to the ER for further assessment.  No notable GI symptoms; at baseline eating, activity, and urination. No respiratory worsening. Fastbreak protocol was initiated with central/peripheral blood cultures drawn, fluid bolus and cefepime given.  CBC demonstrated persistent neutropenia with ANC 430.  CMP with mild transaminitis.  Procal 1.04 without evidence of bacterial pneumonia on CXR.  UA was negative for infection. He was admitted for further monitoring and treatment.  He was started on IV Remdesivir with loading dose (1mg/kg) given overnight and subsequent doses (0.5mg/kg) scheduled daily; maintained in severe respiratory precautions.    On 12/8, CBC showed worsening anemia and he received 1 unit pRBCs with excellent response.  He was continued on empiric Cefepime through 12/10. Blood cultures were NGTD at > 48 hours. He completed remdesivir 3 day course as clinically he remained well without significant complication of Covid infection. He had no further fevers during admission. CBC and CMP continued to be monitored daily and by the time of discharge, ANC was overall stable at 380.  Day 31 therapy was deferred to 12/11 with f/up scheduled in the PHO clinic.  It was discussed that he should remain with masking precautions for ongoing Covid infection for 21 days given immunocompromise and prolonged viral shedding with additional isolation as able thru 12/12 (apart from necessary medical appointments).   Father was advised to return for any further fevers > 101F and for worsening respiratory status as this could be indication of secondary bacterial pneumonia. All questions answered. Port was de-accessed prior to discharge.   His next LP will be deferred to 1/8/2024 with start of maintenance therapy.
Age: 5.0
Sex: M
Vaccine: MMRV
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Patient presents to Family practice to "establish care and update on immunizations". Immunizations in EPIC reflects that patient is overdue for all immunizations. Patient was seen by Peds Oct 2022 and in that office visit it was documented that grandma does have immunizations records on her phone. Peds did not update WIR with immunizations records from grandma. I went off of copy immunizations given by grandmother and gave patient Proquad, COVID, and flu. After documenting immunizations in EPIC, writer realized that patient already received Proquad last year at Peds and he received his 12 months immunization which includes varicella and MMR.  Patient waited for 15-20 minutes with grandmother without any side effects and was discharged home.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Mobility decreased, Painful respiration
Clinical narrative: patient reported  more than two months after vaccine administration that he has some pain in right arm area and not 100% mobility since receiving immunization in october. He reported to PCP who stated that he was not able to assign the issue to be immunization related at this time. patient was instructed by PCP to schedule an orthopedic appointment for discomfort/mobility. The patient was able to lift his arm when presenting at the pharmacy area on 12/14 and stated that morning he was able to place his arm inside his coat.
Age: 54.0
Sex: M
Vaccine: FLU4
Symptoms: Shoulder injury related to vaccine administration
Clinical narrative: on 12/20/2023 the patient called into our support center to report having SIRVA following administration of this vaccine.  patient stated issues started in 12/2021, but no diagnosis given until recently.
Age: 2.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, Chest X-ray abnormal, Condition aggravated, Cough
Clinical narrative: Discharge Provider: MD  Primary Care Physician at Discharge: MD Admission Date: 12/6/2023  Discharge Date: 12/14/2023 DETAILS OF HOSPITAL STAY: COVID [U07.1] Acute hypoxic respiratory failure (HCC) [J96.01] COVID-19 [U07.1]   HOSPITAL COURSE:   Patient is a 3 y.o. female with PMHx HIE, CLD, CP w/ GDD, dysphagia w/ gtube dependence, focal epilepsy, and sialorrhea who was admitted for acute hypoxic respiratory failure 2/2 COVID and superimposed pneumonia.    Patient initially started symptoms of cough and congestion on 12/3. She had elevated fevers of 102-103 F. She then progressed to having increased work of breathing on 12/5 which prompted her to be evaluated in the ED.    Upon arrive, the patient was placed on high flow nasal cannula. Viral studies were conducted and found to be positive for COVID. An x ray was performed which showed a right upper lobe opacity concerning for pneumonia. She received breathing treatments without benefit. She was admitted to the PICU for further care. She was advanced from HFNC to BiPAP. She was weaned to NIPPV on 12/7 and then to CPAP on 12/8. She was receiving scheduled breathing treatments. She completed 5 days of remdesivir and 5 days of antibiotics for pneumonia. She did receive steroid treatment. She was given g tube feedings at a continuous rate initially due to her respiratory status. She was slowly tapered to room air and returned to her normal feeds. Pulmonology was consulted to evaluate her for a vest for airway clearance, which was ordered. A CXR was ordered which was improved. On 12/14, she was deemed stable for discharge and will follow up with her PCP and necessary specialists (pulmonology, neurology). She will complete her 5 day orapred burst at home.
Age: 2.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Feeding tube user, Intensive care, Lung opacity, Mechanical ventilation
Clinical narrative: Discharge Provider: MD  Primary Care Physician at Discharge: MD Admission Date: 12/6/2023  Discharge Date: 12/14/2023 DETAILS OF HOSPITAL STAY: COVID [U07.1] Acute hypoxic respiratory failure (HCC) [J96.01] COVID-19 [U07.1]   HOSPITAL COURSE:   Patient is a 3 y.o. female with PMHx HIE, CLD, CP w/ GDD, dysphagia w/ gtube dependence, focal epilepsy, and sialorrhea who was admitted for acute hypoxic respiratory failure 2/2 COVID and superimposed pneumonia.    Patient initially started symptoms of cough and congestion on 12/3. She had elevated fevers of 102-103 F. She then progressed to having increased work of breathing on 12/5 which prompted her to be evaluated in the ED.    Upon arrive, the patient was placed on high flow nasal cannula. Viral studies were conducted and found to be positive for COVID. An x ray was performed which showed a right upper lobe opacity concerning for pneumonia. She received breathing treatments without benefit. She was admitted to the PICU for further care. She was advanced from HFNC to BiPAP. She was weaned to NIPPV on 12/7 and then to CPAP on 12/8. She was receiving scheduled breathing treatments. She completed 5 days of remdesivir and 5 days of antibiotics for pneumonia. She did receive steroid treatment. She was given g tube feedings at a continuous rate initially due to her respiratory status. She was slowly tapered to room air and returned to her normal feeds. Pulmonology was consulted to evaluate her for a vest for airway clearance, which was ordered. A CXR was ordered which was improved. On 12/14, she was deemed stable for discharge and will follow up with her PCP and necessary specialists (pulmonology, neurology). She will complete her 5 day orapred burst at home.
Age: 2.0
Sex: F
Vaccine: COVID19
Symptoms: Pneumonia, Positive airway pressure therapy, Pyrexia, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: Discharge Provider: MD  Primary Care Physician at Discharge: MD Admission Date: 12/6/2023  Discharge Date: 12/14/2023 DETAILS OF HOSPITAL STAY: COVID [U07.1] Acute hypoxic respiratory failure (HCC) [J96.01] COVID-19 [U07.1]   HOSPITAL COURSE:   Patient is a 3 y.o. female with PMHx HIE, CLD, CP w/ GDD, dysphagia w/ gtube dependence, focal epilepsy, and sialorrhea who was admitted for acute hypoxic respiratory failure 2/2 COVID and superimposed pneumonia.    Patient initially started symptoms of cough and congestion on 12/3. She had elevated fevers of 102-103 F. She then progressed to having increased work of breathing on 12/5 which prompted her to be evaluated in the ED.    Upon arrive, the patient was placed on high flow nasal cannula. Viral studies were conducted and found to be positive for COVID. An x ray was performed which showed a right upper lobe opacity concerning for pneumonia. She received breathing treatments without benefit. She was admitted to the PICU for further care. She was advanced from HFNC to BiPAP. She was weaned to NIPPV on 12/7 and then to CPAP on 12/8. She was receiving scheduled breathing treatments. She completed 5 days of remdesivir and 5 days of antibiotics for pneumonia. She did receive steroid treatment. She was given g tube feedings at a continuous rate initially due to her respiratory status. She was slowly tapered to room air and returned to her normal feeds. Pulmonology was consulted to evaluate her for a vest for airway clearance, which was ordered. A CXR was ordered which was improved. On 12/14, she was deemed stable for discharge and will follow up with her PCP and necessary specialists (pulmonology, neurology). She will complete her 5 day orapred burst at home.
Age: 2.0
Sex: F
Vaccine: COVID19
Symptoms: Superinfection
Clinical narrative: Discharge Provider: MD  Primary Care Physician at Discharge: MD Admission Date: 12/6/2023  Discharge Date: 12/14/2023 DETAILS OF HOSPITAL STAY: COVID [U07.1] Acute hypoxic respiratory failure (HCC) [J96.01] COVID-19 [U07.1]   HOSPITAL COURSE:   Patient is a 3 y.o. female with PMHx HIE, CLD, CP w/ GDD, dysphagia w/ gtube dependence, focal epilepsy, and sialorrhea who was admitted for acute hypoxic respiratory failure 2/2 COVID and superimposed pneumonia.    Patient initially started symptoms of cough and congestion on 12/3. She had elevated fevers of 102-103 F. She then progressed to having increased work of breathing on 12/5 which prompted her to be evaluated in the ED.    Upon arrive, the patient was placed on high flow nasal cannula. Viral studies were conducted and found to be positive for COVID. An x ray was performed which showed a right upper lobe opacity concerning for pneumonia. She received breathing treatments without benefit. She was admitted to the PICU for further care. She was advanced from HFNC to BiPAP. She was weaned to NIPPV on 12/7 and then to CPAP on 12/8. She was receiving scheduled breathing treatments. She completed 5 days of remdesivir and 5 days of antibiotics for pneumonia. She did receive steroid treatment. She was given g tube feedings at a continuous rate initially due to her respiratory status. She was slowly tapered to room air and returned to her normal feeds. Pulmonology was consulted to evaluate her for a vest for airway clearance, which was ordered. A CXR was ordered which was improved. On 12/14, she was deemed stable for discharge and will follow up with her PCP and necessary specialists (pulmonology, neurology). She will complete her 5 day orapred burst at home.
Age: 54.0
Sex: F
Vaccine: MNQ
Symptoms: No adverse event, Product preparation issue
Clinical narrative: Vaccine was not reconstituted properly. No side effects  were  reported by patient
Age: 66.0
Sex: F
Vaccine: RSV
Symptoms: Injection site erythema, Joint swelling
Clinical narrative: Left shoulder became swollen around the joint. Area is erythematous around injection site. Injection site is located near the joint area. Symptoms started on 12/9/23 within 48 hours after the administration of the injection given on 12/7/23. Patient has been doing warm/cold compresses.  Referral to Orthopedics was made 12/20/23 at follow up visit and assessment of the site by PA for further evaluation of the joint site.
Age: 60.0
Sex: M
Vaccine: FLU4
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: No harm to patient, pt received high dose flu vaccine and is not over 65 years of age
Age: 45.0
Sex: F
Vaccine: COVID19, FLUC4
Symptoms: Extra dose administered, No adverse event
Clinical narrative: On 12/13/2023, during the flu and Covid 19 pre-vaccination check patient was asked if she received flu or Covid vaccination in the last 12 months.  Patient stated:? No, I had no vaccine in the last 12 months?. Flu vaccine was administered, and no adverse or allergic reactions were noted. After entering the vaccine administration into our electronic health record, we noticed that patient received flu vaccine in September 2023 from different organization. I contacted the patient and asked her to confirm previous flu vaccine. Patient stated: ?Yes, I received the flu vaccine in September 2023?. When asked, why she did not report the vaccine during pre-vaccination check, patient stated: ?I forgot, we have to many vaccines to remember?. When asked if she experienced any adverse or allergic reaction after vaccine administration, patient stated:? No, I feel good?.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: Patient was given Moderna 0.25 mL covid vaccine instead of the Moderna 0.5 mL covid vaccine.
Age: 62.0
Sex: F
Vaccine: FLU4
Symptoms: Limb mass, Mobility decreased, Myositis, Pain, Pain in extremity
Clinical narrative: Onset of arm pain followed by pain with use and difficulty  w/ forward reach, adduction and overhead use of left arm - lump in arm. Denies other known trauma to this arm from 10/27/2023 to this date 12/20/2023 Onset within 48 hours of injection  on 10/29/2023 -did not resolve  or improved with conservative care , OTC treatment and continued pain with any use of the arm when attempting to flex, abduct/adduct at shoulder/upper arm level.  Sent to Occupational clinic on 12/12/2023 - diagnosed myositis  and prescribed Prednisone taper.  12/20/2023 follow up post prednisone taper with improved overhead and flexion activity with continued pain and reduction in ADduction of left arm and a "lump" felt to deltoid musculature. have requested OT services for ROM and desensitization of the left upper arm
Age: 4.0
Sex: M
Vaccine: DTAPIPV
Symptoms: Rash
Clinical narrative: RASH
Age: 1.0
Sex: F
Vaccine: TDAP
Symptoms: Injection site erythema, Injection site pain
Clinical narrative: Donor received immunization on 12/15/23 at 16:43. Donor states symptoms starting about 30-36 hrs later. Donor states pain and tenderness on immunization site 5/10 on 12/16/23 and the site became red on 12/19/23.
Age: 78.0
Sex: F
Vaccine: RSV
Symptoms: Fatigue, Head discomfort, Headache
Clinical narrative: I started getting a headache about 3 hours after the shot. It felt like a band of pressure around the top of my head. It is a little better today but I do have extreme exhaustion.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Acoustic stimulation tests, Deafness
Clinical narrative: hearing loss in my left ear for 3 days that improved with steroids, but not back to it's base level
Age: 76.0
Sex: M
Vaccine: UNK
Symptoms: Disorientation, Dizziness postural, Eye disorder
Clinical narrative: If he tries to stand up from a lying down position he gets extremely dizzy and lasts for a while. It happened this morning and this afternoon. His eyes weren't operating together and one seemed to be wandering around and he seemed disoriented. He seemed to recover after about 15 minutes.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: arm issues
Age: 68.0
Sex: F
Vaccine: RSV
Symptoms: Arthralgia, Chills, Injection site pain, Lethargy
Clinical narrative: In the several hours after vaccination I felt mild lethargy and minimal injection site soreness. However at 11 hours post vaccination I developed a rapid onset of SEVERE uncontrollable RIGORS and joint pain (posterior neck, left shoulder, spine, left knee and both hips. I had no fever, nausea/vomiting, rash or lip/tongue swelling.  The rigors and joint pain were unrelenting until I took Motrin 400 mg after which they diminished after 30 minutes or so.  (The rigors were so severe  and rapid that I couldn't hold the bottle of Motrin without tablets flying out of the bottle onto the floor)
Age: 4.0
Sex: M
Vaccine: FLU4
Symptoms: Injection site swelling, Peripheral swelling
Clinical narrative: Started with arm swelling 12/18/23 at the injection site. By 12/20/23 AM arm was swollen from shoulder to mid forearm, past the elbow.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Abscess limb, Asthenia, Blood test abnormal, Decreased appetite, Dyspnoea exertional
Clinical narrative: 2 weeks after shot started developing an access on left knee.  Weakness,  DOE, loss appetite.  Blood work concerning for leukemia
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: MOderna vaccine was removed from the freezer on 11/10/2023 and refrigerated beyond use date was 12/10/2023. It was administered to patient  1 day past the beyond use date on 12/11/2023.   No adverse reaction reported
Age: 69.0
Sex: M
Vaccine: COVID19, PNC20
Symptoms: No adverse event, Product storage error
Clinical narrative: MOderna vaccine was removed from the freezer on 11/10/2023 and refrigerated beyond use date was 12/10/2023. It was administered to patient  1 day past the beyond use date on 12/11/2023.   No adverse reaction reported
Age: 41.0
Sex: M
Vaccine: COVID19, FLU4
Symptoms: Loss of consciousness, Urinary incontinence
Clinical narrative: Patient briefly passed out, in the immunizing chair in our immunizing booth, once he received both vaccinations in his left arm (patient did not want them in separate arms.)  He urinated on himself and immediately regained consciousness.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Computerised tomogram head, Hypoaesthesia
Clinical narrative: pfizer 1st dose, had Moderna in the past with out reaction , left face, arm and leg numbness reported during the 15 minute observation period, taken to ER for further evaluation
Age: 80.0
Sex: M
Vaccine: COVID19, FLU4, RSV
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: MOderna vaccine was removed from the freezer on 11/10/2023 and refrigerated beyond use date was 12/10/2023. It was administered to patient  5 days past the beyond use date on 12/15/2023.   No adverse reaction reported
Age: 85.0
Sex: M
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Itchy rash all over body,
Age: 2.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Patient was here for 2-year-old well child visit and received a dose of the covid vaccine. Inadvertently, the wrong dose of 12+ was given to the patient, when they should have received the 6months-11-year-old dose. When going to document the vaccine, I noticed my error in dosage. I immediately notified the Attending physician and parent of any possible side effects that they should look out for. VAERS report also will be filled out. No further need for revaccination.
Age: 27.0
Sex: F
Vaccine: COVID19-2
Symptoms: Tinnitus
Clinical narrative: Tinnitus in left ear within weeks of receiving the vaccine. No other changes to my health occurred that would have caused the tinnitus.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Myoclonic epilepsy, Seizure
Clinical narrative: event: myoclonic epilepsy (seizures) 10 to 15 seizures each day since vaccine. never had seizures prior to vaccine.
Age: 62.0
Sex: M
Vaccine: FLU4, VARZOS
Symptoms: Joint range of motion decreased, Mobility decreased, Musculoskeletal stiffness, Pain, Periarthritis
Clinical narrative: The patient reported experiencing stiffness and difficulty moving his arm, starting 09.15.2023 and worsening thereafter. He began experiencing pain and was eventually unable to lift his arm or rotate his shoulder. The patient sought medical treatment for his symptoms in October, approximately 3 weeks after onset. He states he was diagnosed with frozen arm syndrome / SIRVA and that he is receiving physical therapy to treat it.
Age: 62.0
Sex: M
Vaccine: FLU4, VARZOS
Symptoms: Shoulder injury related to vaccine administration
Clinical narrative: The patient reported experiencing stiffness and difficulty moving his arm, starting 09.15.2023 and worsening thereafter. He began experiencing pain and was eventually unable to lift his arm or rotate his shoulder. The patient sought medical treatment for his symptoms in October, approximately 3 weeks after onset. He states he was diagnosed with frozen arm syndrome / SIRVA and that he is receiving physical therapy to treat it.
Age: 9.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain in extremity, Pallor, Vomiting
Clinical narrative: Patient was given vaccine and a few minutes later, pt complained of soreness in arm and headache.  She did look pale.  She also spit up a little bit.  She drank some water and felt fine.  She also had crackers.  After 15 minutes, patient felt good and left with parents
Age: 66.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: Pfizer COVID Vaccine EUA: Pt received vaccine after expiration date Patient received Pfizer Bivalent Vaccine on 12/15/2023. Pt received Pfizer Bivalent vaccine as 7 dose in series on 12/13/2023 after its best use dating of 12/11/23. No treatment needed and no harm came to patient.
Age: 38.0
Sex: M
Vaccine: CHOL, HEPA, TDAP
Symptoms: Syncope
Clinical narrative: Pt received vaccines, no s/s of adverse affects.  Pt fainted and resolved within 5 seconds.  Pt placed supine on exam table and observed for 20 minutes.  No s/s of side effects.
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: Pfizer COVID Vaccine EUA: Pt received vaccine after expiration date Patient received Pfizer Bivalent Vaccine on 12/13/2023. Pt received Pfizer Bivalent vaccine as 6 dose in series on 12/13/2023 after its best use dating of 12/11/23. No treatment needed and no harm came to patient.
Age: 76.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Pfizer COVID Vaccine EUA: Pt received vaccine after expiration date Patient received Pfizer Bivalent Vaccine on 12/13/2023. Pt received Pfizer Bivalent vaccine as 6 dose in series on 12/13/2023 after its best use dating of 12/11/23. No treatment needed and no harm came to patient.
Age: 61.0
Sex: F
Vaccine: COVID19, FLU4, VARZOS
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: MOderna vaccine was removed from the freezer on 11/10/2023 and refrigerated beyond use date was 12/10/2023. It was administered to patient  4 days past the beyond use date on 12/14/2023.   No adverse reaction reported
Age: 65.0
Sex: M
Vaccine: COVID19-2
Symptoms: Joint range of motion decreased, Pain in extremity
Clinical narrative: pain and limited range of motion in the left arm (long term)
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, FLU4
Symptoms: Ageusia, Anosmia, Fatigue, Headache, Nausea
Clinical narrative: Extreme headache and naussa for several days. After which the loss of taste and a loss of degree of smell. The presence of naussa everyday caused a weight loss of over 25 lbs from 145lbs to 120. To date no symptoms have ever dissipated. No other boosters were recieved. On 12/19/2023 a routine Flu Shot was received by Dr's recommendation, extreme adverse effects were realized again, similiar to that of this report. Extreme naussa, headache, fatique, lasting now for over 30hrs. This recent flu shot was the first since 2018
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, FLU4
Symptoms: Weight decreased
Clinical narrative: Extreme headache and naussa for several days. After which the loss of taste and a loss of degree of smell. The presence of naussa everyday caused a weight loss of over 25 lbs from 145lbs to 120. To date no symptoms have ever dissipated. No other boosters were recieved. On 12/19/2023 a routine Flu Shot was received by Dr's recommendation, extreme adverse effects were realized again, similiar to that of this report. Extreme naussa, headache, fatique, lasting now for over 30hrs. This recent flu shot was the first since 2018
Age: 49.0
Sex: M
Vaccine: FLUC4
Symptoms: Arthralgia, Product administered at inappropriate site
Clinical narrative: Patient said the technician administered the vaccine too high and has had really bad shoulder pain since the date of vaccination.
Sex: F
Vaccine: HEP
Symptoms: Hepatitis B surface antibody negative, Underdose
Clinical narrative: they have restarted the Hepatitis vaccination series on a patient due to it not showing in the patients tithers; the adult patient inadvertently received a pediatric dose of RECOMBIVAX HB.; This spontaneous report was received from registered nurse regarding a female patient of unspecified age.  The patient's relevant medical history, concurrent conditions, and concomitant therapies were not reported.   On an unspecified date, the patient received vaccination with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) (strength, dose description, route of administration, frequency, lot #, and expiration date were not reported). However, the vaccination did not show the tithers in the patient (Hepatitis B surface antibody negative). Therefore, it was determined to restart the vaccination series using Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB). Then, on 21-NOV-2023, the patient started a new series of vaccination with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) 0.5 ml, intramuscularly for the prevention of hepatitis B Virus (Lot # X017743 was a valid number with expiration date on 21-FEB-2026). However, it was noticed that inadvertently the patient had received a pediatric dose of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) (Incorrect dose administered). The patient would return later to obtain the correct dose. At the time of the report, the outcome of the event Hepatitis B surface antibody negative was negative.   The causal relationship between Hepatitis B surface antibody negative and Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) was unknown.
Sex: F
Vaccine: HPV9
Symptoms: Cold sweat, Dyspnoea, Palpitations
Clinical narrative: chest palpitations; cold sweats; difficulty breathing; This spontaneous report was received from pharmacy manager and refers to a female of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On unknown date, the patient was vaccinated with first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, (0.5 milliliter, intramuscularly, lot #, expiration date and anatomical location were not provided) for prophylaxis.  On unknown date, the patient experienced chest palpitations, cold sweats and difficulty breathing. At the time of reporting, the outcome of the events was not known. The action taken with suspect vaccine regarding the events was reported as not applicable.   The causal relationship between the events and hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was not provided.